Oligonucleotide-Based Anti-monkeypox Drug Discovery Solutions

Monkeypox is a rare disease caused by monkeypox virus infection. In recent years, the monkeypox disease has concentrated and spread rapidly. Based on our extensive experience and advanced platforms, now Creative Biolabs provides novel oligonucleotide-based anti-monkeypox drug discovery solutions for our clients all over the world.

Overview of Antisense Oligonucleotides

Antisense oligonucleotides (ASOs) are synthetic chains of nucleotides targeting almost any genes of interest. In general, an ASO bind to the transcribed messenger RNA (mRNA) of the target gene via Watson-Crick base pairing or Hoogsteen base pairing. Both binding models have the potential to modulate gene expression and thus serve as attractive potential alternatives to conventional antiviral agents. Compared with traditional drugs targeting proteins, ASO is simple in design and has higher specificity. However, there are always unwanted side effects of the ASO, such as instability and delivery. To further improve the efficacy of ASOs, the base, sugar, or phosphate backbone of oligonucleotides can be chemically modified.

Figure.1 Mechanism of action of antisense RNA. (Reza, 2021)

• Antisense oligoribonucleotide-based Solutions

Antisense oligoribonucleotides are short fragments of RNA to influence the functions of target DNAs or RNAs to which they hybridize. Antisense oligoribonucleotides have been proved to be effective gene expression inhibitors with the ability to inhibit retroviral replication at multiple stages of the viral life cycle. Binding to specific mRNAs and preventing the translation of proteins is the rationale for their emergence as an effective therapeutic agent. For example, the packaging signal (Ψ) of HIV-1 is an attractive target for antisense oligoribonucleotide-based gene therapy. What's more, antisense oligoribonucleotide targeting the HBsAg coding region can specifically inhibit envelope protein synthesis against the hepatitis B virus (HBV).

Figure.2 Mechanism of action of antisense oligonucleotides. (Reza, 2021)

• Antisense oligodeoxyribonucleotide-based Solution

The antisense oligodeoxyribonucleotides (AODNs) refer to synthetic single-stranded DNA oligonucleotides with a length of 12-30 nt. Once inside the cell, AODNs pair with their targets to block ribosomal translation and stimulate the degradation of RNA:DNA hybrids by the cellular RNase H enzyme. Therefore, the expression of RNase H is positively correlated with the action of AODN. However, some AODNs cannot activate RNase H but inhibit gene translation by sterically competing with the translation machinery. In addition, AODN can also disrupt splicing or RNA trafficking through multiple pathways.

Till now, AODNs have been widely applied against a variety of human viral pathogens, including human papillomavirus (HPV), human immunodeficiency virus (HIV), respiratory syncytial virus, and vesicular stomatitis virus, etc. For example, Vitravene is the first FDA-approved AODN drug for the treatment of cytomegalovirus (CMV) induced retinitis.

Features of our Anti-Monkeypox Drug Discovery Services

• Advanced platforms to ensure the best achievement for every single step.
• Fully customizable experimental design to expand beyond standard procedure.
• Competitive price with the best quality.
• Reliable lab report with timely updates.

Creative Biolabs is a leading service provider that focuses on anti-monkeypox drug development. We can assist you in designing the best research outline customized to meet the requirements of clients' programs. If you are interested in our services and products, please do not hesitate to contact us for more details.